Technology evaluation: ABX-EGF, Abgenix/Amgen.
Abgenix and Amgen (formerly Immunex) are developing ABX-EGF, a human monoclonal antibody against the epidermal growth factor receptor, for potential use in the treatment of cancer. ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003.
Ranson
Malcolm
M
University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. malcolm.ranson@man.ac.uk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab; D066246:ErbB Receptors